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Abstract
Carbon monoxide (CO) is emerging as an important and versatile mediator of physiological processes to
the extent that treatment of animals with exogenous CO gas has beneficial effects in a range of vascular-
and inflammatory-related disease models. The recent discovery that certain transition metal carbonyls
function as CO-releasing molecules (CO-RMs) in biological systems highlighted the potential of
exploiting this and similar classes of compounds as a stratagem to deliver CO for therapeutic purposes.
Here we describe the biochemical features and pharmacological actions of a newly identified
water-soluble CO releaser (CORM-A1) that, unlike the first prototypic molecule recently described
(CORM-3), does not contain a transition metal and liberates CO at a much slower rate under
physiological conditions. Using a myoglobin assay and an amperometric CO electrode, we demonstrated
that the release of CO from CORM-A1 is both pH- and temperature-dependent with a half-life of
approximately 21 min at 37 degrees C and pH 7.4. In isolated aortic rings, CORM-A1 promoted a
gradual but profound concentration-dependent vasorelaxation over time, which was highly amplified by
YC-1 (1 microM) and attenuated by ODQ, a stimulator and inhibitor of guanylate cyclase, respectively.
Similarly, administration of CORM-A1 (30 micromol/kg i.v.) in vivo produced a mild decrease in mean
arterial pressure, which was markedly potentiated by pretreatment with YC-1 (1.2 micromol/kg i.v.).
Interestingly, an inactive form of CORM-A1 that is incapable of releasing CO failed to promote both
vasorelaxation and hypotension, thus directly implicating CO as the mediator of the observed
pharmacological effects. Our results reveal that the bioactivities exerted by CORM-A1 reflect its
intrinsic biochemical behavior of a slow CO releaser, which may be advantageous in the treatment of
chronic conditions that require CO to be delivered in a carefully controlled manner.
 ©2004 FASEB 
The FASEB Journal express article10.1096/fj.04-2169fje. Published online November 19, 2004. 
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ABSTRACT 
Carbon monoxide (CO) is emerging as an important and versatile mediator of physiological 
processes to the extent that treatment of animals with exogenous CO gas has beneficial effects in 
a range of vascular- and inflammatory-related disease models. The recent discovery that certain 
transition metal carbonyls function as CO-releasing molecules (CO-RMs) in biological systems 
highlighted the potential of exploiting this and similar classes of compounds as a stratagem to 
deliver CO for therapeutic purposes. Here we describe the biochemical features and 
pharmacological actions of a newly identified water-soluble CO releaser (CORM-A1) that, 
unlike the first prototypic molecule recently described (CORM-3), does not contain a transition 
metal and liberates CO at a much slower rate under physiological conditions. Using a myoglobin 
assay and an amperometric CO electrode, we demonstrated that the release of CO from CORM-
A1 is both pH- and temperature-dependent with a half-life of ~21 min at 37°C and pH 7.4. In 
isolated aortic rings, CORM-A1 promoted a gradual but profound concentration-dependent 
vasorelaxation over time, which was highly amplified by YC-1 (1 µM) and attenuated by ODQ, 
a stimulator and inhibitor of guanylate cyclase, respectively. Similarly, administration of CORM-
A1 (30 µmol/kg i.v.) in vivo produced a mild decrease in mean arterial pressure, which was 
markedly potentiated by pretreatment with YC-1 (1.2 µmol/kg i.v.). Interestingly, an inactive 
form of CORM-A1 that is incapable of releasing CO failed to promote both vasorelaxation and 
hypotension, thus directly implicating CO as the mediator of the observed pharmacological 
effects. Our results reveal that the bioactivities exerted by CORM-A1 reflect its intrinsic 
biochemical behavior of a slow CO releaser, which may be advantageous in the treatment of 
chronic conditions that require CO to be delivered in a carefully controlled manner. 
Key words: sodium boranocarbonate • CO electrode • vascular tone • blood pressure • heme 
oxygenase-1 
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espite being notorious for its insidious and toxic effects, carbon monoxide (CO) is now 
recognized as a ubiquitous cellular mediator capable of controlling fundamental 
physiological and signaling processes in mammalian tissues (1). The paradigm of a 
potentially noxious molecule playing a crucial biological role at low concentrations should not 
be totally unexpected as CO is continuously generated in the cell through the degradation of 
heme by constitutive (HO-2) and inducible (HO-1) heme oxygenase proteins (2) and the local 
production of CO can be markedly increased upon activation of HO-1 (3, 4). This sensitive 
inducible enzyme, which beside CO generates the antioxidants biliverdin/bilirubin, is now 
regarded as an obligatory protective system necessary to restore the redox imbalance inflicted on 
cells and tissues by various forms of oxidative and nitrosative stress (5–10). Notably, the 
pleiotropic properties attributed to HO-1 within the cardiovascular, nervous, and immune 
systems dovetail with the multiplicity of activities that so far has also been ascribed to CO. 
Endogenous CO exerts vasodilatory effects through stimulation of soluble guanylate cyclase (4, 
11, 12) and appears to alleviate acute hypertension in vivo as well as vascular resistance in the 
hepatic circulation (3, 13). Moreover, HO-1-derived CO controls the proliferation of vascular 
smooth muscle cells (14, 15), prolongs the survival of transplanted organs (16), and improves 
vascular reactivity of the mesenteric circulation in hepatic cirrhosis (17). The biological effects 
mediated by endogenous CO can be simulated when this gas is applied exogenously; this 
strategic approach revealed a variety of beneficial actions of CO, including potent anti-
inflammatory and anti-apoptotic effects (18–20), suppression of atherosclerotic lesions following 
aortic transplantation (21), prevention of reperfusion-induced ventricular fibrillation in the 
myocardium (22), and protection against ischemic lung injury (23). The encouraging outcome of 
these studies led scientists to the tantalizing concept that CO could be used for therapeutic 
purposes in the treatment of vascular dysfunction and inflammatory disease states. 
 
The discovery of compounds capable of carrying and delivering CO to tissues and organs would 
undoubtedly accelerate and facilitate the development of novel pharmaceutical agents suitable 
for therapeutic applications (24–26). Ideally, this stratagem could offer significant advantages 
over inhalation of CO gas as it may circumvent the problems related to the systemic effects 
imposed by CO on oxygen transport and delivery (27). Indeed, the therapeutic use of gas 
mixtures poses obvious limitations, not least the difficulty of storing and delivering CO in a 
controlled-directed fashion. To avoid these practical obstacles, we have focused on developing 
molecules having the inherent ability to liberate CO under appropriate conditions and function as 
CO-releasing molecules (CO-RMs) in biological systems. The first class of such compounds we 
evaluated are a group of transition metal carbonyls (28). Specifically, two carbonyl complexes 
initially identified as possessing CO-releasing properties were manganese decacarbonyl 
([Mn2(CO)10]) and tricarbonyldichlororuthenium(II) dimer ([Ru(CO)3Cl2]2) (termed CORM-1 
and CORM-2, respectively [24]). Although these two compounds are soluble only in organic 
solvents and CORM-1 requires irradiation to induce CO loss, they both proved to be 
pharmacologically active by exerting effects that are typical of CO gas, including vessel 
relaxation, attenuation of coronary vasoconstriction, and suppression of acute hypertension (29). 
Subsequently, we made further progress by synthesizing the first prototype of a water-soluble 
CO-RM; this was attained primarily to overcome the solubility constraints and the fact that the 
majority of carbonyl-based compounds described in the literature requires physical (e.g., 
irradiating light) or chemical (e.g., ligand substitution) stimuli to promote CO dissociation (28). 
Tricarbonylchloro(glycinato)ruthenium(II) (CORM-3), which can be obtained by coordinating 
D 
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the amino acid glycine onto the metal center, is fully soluble in water and rapidly liberates CO in 
vitro, ex vivo, and in vivo biological models (24). Interestingly, based on the evidence that CO 
gas is beneficial against oxidative-stress-mediated damage (20) and prevents organ rejection 
following transplantation (16), we and our collaborators reported that CORM-3 protects 
myocardial tissues against ischemia-reperfusion injury both ex vivo (30) and in vivo (31) and 
prolongs the survival of cardiac allografts in mice (30). More recently, we have provided 
evidence for important vasodilatory properties of CORM-3 through mechanisms that involve 
guanylate cyclase and potassium channel activation (32). Thus, initial studies confirmed that 
transition metal carbonyls are versatile complexes that can be chemically modified to meet the 
criteria of biologically active CO carriers. 
In our persistent search for agents that could be safely used as CO-RMs in biological systems, 
we have identified sodium boranocarbonate (Na2[H3BCO2], here termed CORM-A1) as an 
extremely promising water-soluble compound that spontaneously liberates CO in aqueous 
solutions. CORM-A1 differs from the original CO-RMs as it does not contain a transition metal 
and releases CO with a slower rate compared with CORM-3. Here we report on the biochemical 
reactivity and pharmacological effects of CORM-A1 and discuss how its properties of a “slow” 
CO releaser could be exploited in a therapeutic context. 
MATERIALS AND METHODS 
Preparation of chemicals and solutions 
CORM-A1 was prepared as described previously by Alberto and coworkers (33). CORM-3 was 
synthesized as recently reported by our group (30, 32). Stock solutions of CORM-3 and CORM-
A1 (10–100 mM) were freshly prepared before the experiments by dissolving the compounds in 
pure distilled water. In our preliminary tests, we noticed that acidic pHs significantly accelerate 
the spontaneous release of CO from CORM-A1. We therefore took advantage of this specific 
property of CORM-A1 and generated a CO-depleted inactive form (iCORM-A1) to be used as a 
negative control by initially dissolving CORM-A1 in 0.1 M HCl and then bubbling pure N2 
through the solution for 10 min in order to remove the residual CO gas. The solution of iCORM-
A1, which is probably predominantly sodium borate (33), was finally adjusted to pH 7.4 and 
tested with the myoglobin assay (see below) before each experiment to verify its inability to 
liberate CO. 1H-(1,2,4)oxadiazole(4,3-a)quinoxalin-1-one (ODQ), glibenclamide, and 3-(5′-
hydroxymethyl-2’-furyl)-1-benzylindazole (YC-1) were from Alexis Corporation (Nottingham, 
UK). All other chemicals used in the study were from Sigma (St. Louis, MO), unless otherwise 
specified. 
Detection of CO release using the myoglobin assay 
The release of CO from CORM-A1 was assessed spectrophotometrically by measuring the 
conversion of deoxymyoglobin (deoxy-Mb) to carbonmonoxy myoglobin (MbCO) as previously 
reported by our group (24, 29, 30). A small aliquot of concentrated CORM-A1 solution was 
added to 1 ml deoxy-Mb solution in phosphate buffer (final concentrations: CORM-A1 60 µM; 
deoxy-Mb 53 µM), and changes in the Mb spectra were recorded over time. The amount of 
MbCO formed was quantified by measuring the absorbance at 540 nm (extinction coefficient = 
15.4 M–1 cm–1). To examine the effect of pH on the rate of CO liberation from CORM-A1, we 
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conducted experiments using solutions of myoglobin in 0.04 M phosphate buffer prepared at 
different pHs (7.4, 7.0, 6.5, and 5.5). The amount of MbCO formed was plotted over time, and 
the half-life of CORM-A1 at different pHs and temperatures was calculated from the fitted 
curves. 
Detection of CO release using an amperometric CO sensor 
The release of CO from CORM-A1 was also detected using a prototype electrode purchased 
from World Precision Instrument (WPI, Stevenage, Herts, UK). This CO electrode is a 
membrane-covered amperometric sensor that has been designed on a basic operating principle 
similar to the nitric oxide (NO) sensor. The CO sensor can be connected to the WPI ISO-NO 
Mark II meter for detection of the current signals, providing that the poise potential is set to a 
different value (900 mV for CO as opposed to 860 mV for NO). In principle, CO diffuses 
through the gas-permeable membrane and is then oxidized to CO2 on the working electrode. This 
oxidation will create a current whose magnitude can be related directly to the concentration of 
CO in solution. The CO sensor was used to generate standard curves and calculate the rates of 
CO release from CORM-A1 at different pHs and temperatures. The electrode was immersed into 
the solutions at different pHs and equilibrated for 30 min before addition of CORM-A1. For the 
experiments conducted at 37, 30, 25, and 20°C, the solutions were maintained at the desired 
temperature using a Grant W6 thermostat (Cambridge). 
Measurement of carboxyhemoglobin (HbCO) levels in human blood exposed to CORM-A1 
Blood from a healthy male volunteer was collected in tubes containing EDTA, aliquoted in four 
Eppendorff tubes, and transferred to a water bath at 37°C. Levels of carboxyhemoglobin (HbCO) 
were measured 15 or 45 min after addition of increasing concentrations of CORM-A1 (0, 4.5, 8, 
and 18 mM) using a blood gas analyzer (Omni Modular System, Roche, Lewes, UK). In a 
different set of experiments, the formation of HbCO was also evaluated in a time-dependent 
manner after addition of 18 mM CORM-A1. 
Aortic ring preparation 
Transverse ring sections prepared from aortas of male adult Sprague Dawley rats (350 g) were 
suspended under 2 g tension in oxygenated Krebs Henseleit buffer as described previously (4, 
29, 32). To establish the potential vasorelaxant effects of CORM-A1, we precontracted aortic 
rings with phenylephrine (1 µM) before addition of the compound at different concentrations 
(40–160 µM). The extent of vasorelaxation over time was determined and compared with the 
effect produced by CORM-3. In another set of experiments, the inactive form (iCORM-A1) and 
sodium borohydride (NaBH4) were used as negative controls to exclude the possibility that 
vasorelaxation was a nonspecific effect of boron compounds or borate. Additional experiments 
were conducted to examine the involvement of cGMP and ATP-dependent potassium channels 
(KATP) in the relaxation mediated by CORM-A1. For this, aortic rings were incubated with the 
inhibitor of guanylate cyclase ODQ (30 µM) or the KATP blocker glibenclamide (10 µM) before 
addition of phenylephrine, respectively. To investigate the possible involvement of NO in the 
relaxation elicited by CORM-A1, a separate group of experiments was performed by treating 
aortic rings with the NO synthase inhibitor NG-nitro-L-arginine-methyl ester (L-NAME, 100 µM) 
30 min before addition of phenylephrine. CORM-A1 was also tested in endothelium-denuded 
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rings. For this, the internal lumen of rings was subjected to gentle rubbing with a fine wooden 
stick and failure to dilate upon addition of acetylcholine was taken as a proof of successful 
endothelium removal. The effect of CORM-A1 on vascular tone was also assessed in the 
presence of the stimulator of soluble guanylate cyclase, YC-1 (1 µM), which was added 30 min 
before phenylephrine. Previous experiments from our group have established that 1 µM YC-1 
does not significantly affect the response of aortic rings to phenylephrine (32). The relaxation 
responses were expressed as percentage of the maximal contraction elicited by phenylephrine. 
Blood pressure monitoring in vivo 
Anesthetized adult Lewis rats (290–330 g) were chronically catheterized, and blood pressure was 
continuously monitored as previously reported (3, 29). Animals were anaesthetized using 
enfluorane as an inhalation anesthetic. Surgical anesthesia was maintained throughout the 
operation using oxygen in combination with enfluorane. Changes in mean arterial pressure 
(MAP) were recorded over time following an intravenous injection of CORM-A1 (30 µmol/kg). 
Similar experiments were performed by administering YC-1 (1.2 µmol/kg, i.v.) to animals 5 min 
before the injection of CORM-A1 or the inactive compound (iCORM-A1). 
Statistical analysis 
Statistical analysis was performed using one-way or two-way ANOVA combined with 
Bonferroni test. Differences were considered to be significant at P < 0.05. 
RESULTS 
CORM-A1 liberates CO in a pH- and temperature-dependent manner 
The spectrophotometric assay that detects the formation of carbonmonoxy myoglobin (MbCO) 
from deoxy-Mb has been shown to be a reliable method for assessing the extent and kinetic of 
CO liberation from CO-RMs (24, 29, 30). The conversion of deoxy-Mb to MbCO can be 
followed over time by measuring the changes in the absorption spectra of this protein. As shown 
in Figure 1A (see curve with filled square), the addition of 60 µM CORM-A1 (Na2[H3BCO2]) to 
a phosphate buffer solution containing Mb at 37°C and pH 7.4 resulted in the gradual change of 
the deoxy-Mb spectrum, which has a maximal absorption peak at 560 nm, into spectra typical of 
MbCO. The Mb appears to be fully saturated 2 h after addition of CORM-A1 (see curve with 
filled diamond in Fig. 1A). Interestingly, the time required to fully saturate Mb with CO liberated 
from CORM-A1 gradually decreased by lowering the pH to 7.0, 6.5, and 5.5 (Fig. 1B–D), 
indicating that the rate of CO release from CORM-A1 is pH-dependent.  
From the curves fitted to the spectral data (Fig. 2A) we can calculate that the half-lives of 
CORM-A1 at 37°C are as follows: 21 min at pH 7.4, 7.1 min at pH 7.0, 3.3 min at pH 6.5, and 
2.5 min at pH 5.5. Predictably, iCORM-A1 did not generate any MbCO (see line with open 
square in Fig. 2A). We have also found that the rate of MbCO formation from CORM-A1 
decreases by gradually lowering the temperature of the solutions (data not shown). Because CO 
is promptly liberated to Mb at pH 5.5, we used these conditions to generate a standard curve that 
clearly indicates that the conversion of the carboxyl group from Na2[H3BCO2] to CO goes to 
completion as one mole of CO is formed per mole of CORM-A1 (Fig. 2B, 2C).  
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CORM-A1 was also tested for its ability to liberate CO using an amperometric electrode 
sensitive to CO. Figure 3 reveals that the results obtained with the CO sensor are in good 
accordance with the ones found with the myoglobin assay. From an initial test (see Fig. 3A), it 
can be observed that the rate of CO release from 100 µM CORM-A1 at 37°C is much faster at 
pH 5.5 (t1/2=2.01 min) than pH 7.4 (t1/2=27.06 min), and the calculated half-lives are comparable 
to the ones obtained with the myoglobin assay. As expected, the CO electrode was completely 
insensitive to iCORM-A1, which does not release CO (Fig. 3A). A standard curve generated at 
pH 5.5 using CORM-A1 in a range between 10 and 50 µM indicated a good linear correlation 
(R2=0.998) between the concentrations used and the electrode response (Fig. 3B). Therefore, a 
concentration of 20 µM CORM-A1 was subsequently used to calculate the rate of CO 
dissociation from CORM-A1 at different pHs and temperatures. From the curves shown in 
Figure 3C, we can calculate that the dissociation rate constants of CO and half-lives of CORM-
A1 at 37°C are as follows: 0.55 × 10−3 s–1 and 21.06 min at pH 7.4; 5.8 × 10−3 s–1 and 1.96 min at 
pH 5.5; 11.0 × 10−3 s–1 and 1.02 min at pH 4.0. In addition, we found that the rate of CO 
generation from CORM-A1 is strictly temperature-dependent as already indicated by the 
myoglobin assay. Specifically, from the curves shown in Figure 3D, we can calculate that the 
initial rate of CO release at pH 5.5 is 6.84 µmol/min at 37°C, 3.83 µmol/min at 30°C, 2.16 
µmol/min at 25°C, and 1.22 µmol/min at 20°C. Thus, the spontaneous liberation of CO from 
CORM-A1 in aqueous solutions is accelerated by decreasing the pH and increasing the 
temperature. 
Formation of carboxyhemoglobin (HbCO) in isolated human blood incubated with CORM-
A1 
The average concentration of human hemoglobin in male subjects is 15 g/dl, which is equivalent 
to 9.6 mM heme. This justifies the choice of mM concentrations of CORM-A1 used in order to 
properly evaluate the kinetics of HbCO formation. As shown in Figure 4A, incubation of human 
blood with CORM-A1 at room temperature resulted in a concentration-dependent increase in the 
levels of HbCO over time. The prolonged release of CO from CORM-A1 is emphasized in the 
data showing that the HbCO levels measured 15 min after addition of any concentration of 
CORM-A1 used are much lower than those measured after 45 min. In fact, when HbCO levels 
were determined at regular intervals over a 2-h period after addition of 18 mM CORM-A1, a 
gradual and time-dependent formation of HbCO was observed (Fig. 4B), with a kinetic very 
similar to the ones observed using the Mb assay. Note that the concentrations of CORM-A1 
needed to produce substantial increases in HbCO are in the mM range, while the 
pharmacological effects in terms of vessel relaxation and decrease in MAP (see results reported 
below) are observed when CORM-A1 is used at low micromolar concentrations. 
Vasodilatory effects of CORM-A1 in isolated aortic rings 
CORM-3 has been shown to promote a rapid and significant relaxation in isolated vessels, and 
this effect has been demonstrated to be mediated by CO (24, 32). Figure 5A shows typical 
isometric recordings from aortic rings precontracted with phenylephrine (Phe) and treated with 
either CORM-3 or CORM-A1. It can be observed that CORM-A1 (80 µM) caused a profound 
but much slower dilatory effect compared with CORM-3 (80 µM). Specifically, CORM-3 (solid 
line) promoted >50% relaxation within 4–5 min whereas CORM-A1 (dashed line) caused a 
gradual vasorelaxation, which was maximal (96%) 33 min following addition of the compound 
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to the organ bath. Precontracted aortic rings were also treated with increasing concentrations of 
CORM-A1 (40, 80, and 160 µM), and vasorelaxation was measured at different time points. As 
shown in Figure 5B, CORM-A1 caused a significant relaxation over time in a concentration-
dependent manner. For instance, the extent of relaxation elicited by the different concentrations 
of CORM-A1 after 10 min was as follows: 21.0 ± 2.3% with 40 µM CORM-A1, 40.2 ± 3.4% 
with 80 µM CORM-A1, and 74.9 ± 1.8% with 160 µM CORM-A1. The maximal relaxation 
mediated by CORM-A1 was reached after 30 min; the rings spontaneously recontracted again 
thereafter, but no vasodilatory effect was observed if a new addition of CORM-A1 was 
performed immediately after recontraction (data not shown). Precontracted aortic rings were also 
treated with 80 µM iCORM-A1 (the inactive compound) or sodium borohydride (NaBH4), which 
was used as an additional negative control to exclude any effect of boron on vessel tone. As 
shown in Figure 6A, 6B, CORM-A1 promoted a gradual and profound vasorelaxation, whereas 
both iCORM-A1 and NaBH4 were totally ineffective. Moreover, the addition of myoglobin (100 
µM) to the organ bath significantly attenuated the vasorelaxation mediated by CORM-A1 (Fig. 
6C). Collectively, these results strongly suggest that CO liberated from CORM-A1 is directly 
responsible for the observed pharmacological effect. 
CO-mediated vasorelaxation by CORM-A1: possible mechanisms of action 
It is well-established that CO, either endogenously generated from HO-1, exogenously applied as 
CO gas, or delivered by CO-RMs to vascular tissues, activates guanylate cyclase to increase the 
production of cGMP (4, 29, 32). A recent report suggested the involvement of ATP-dependent 
(KATP) potassium channels as part of the dilatory mechanisms exerted by CORM-3, a ruthenium-
based water-soluble CO carrier (32). In this study, the vasodilatation caused by CORM-A1 was 
partially inhibited in the presence of a guanylate cyclase blocker (ODQ, 30 µM) but was not 
affected by glibenclamide (GLI, 10 µM), an inhibitor of KATP potassium channels (see Fig. 7A). 
Aortic rings were also pretreated with L-NAME (100 µM) to examine the contribution of the NO 
synthase pathway in CORM-A1-mediated vasorelaxation. Apart from an initial 17 ± 2.4% 
attenuation of the vasodilatory response to CORM-A1 in the first 10 min, the presence of L-
NAME did not considerably change the effect of CORM-A1 thereafter (Fig. 7B). Similarly, 
removal of the endothelium did not alter the potency of relaxation responses to CORM-A1 (Fig. 
7C). These data together suggest that NO and/or factors derived from the endothelium barely 
contribute to the action of CORM-A1 and cooperate with CO in the regulation of aortic vessel 
tone. 
YC-1 potentiates the vasodilatory action of CORM-A1 both in vitro and in vivo 
The benzylindazole derivative, YC-1, is known to sensitize guanylate cyclase to activation by 
CO (34). When rings were preincubated with YC-1 at 1 µM, the vasoactivity of CORM-A1 was 
markedly intensified at all concentrations tested (Fig. 8A), further sustaining the direct 
contribution of guanylate cyclase to the effect elicited by CORM-A1-derived CO. Specifically, 
20 µM CORM-A1 caused 13 ± 4.9% relaxation after 20 min, but a more pronounced and 
significant relaxation response (61±6.2%, P<0.01) was detected after pretreatment of vessels 
with YC-1 (1 µM). Control vessels pretreated with YC-1 alone and contracted with 
phenylephrine also exhibited a degree of relaxation over time (14.1±1.1% after 20 min). 
Interestingly, the rings treated with CORM-A1 in combination with YC-1 did not spontaneously 
recontract after reaching the maximal relaxation. The relaxation response of vessels pretreated 
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with YC-1 was also markedly potentiated (P<0.01) in the presence of 1 µM or 10 µM CORM-
A1 (35±9.8% and 51±3.3%, respectively). These data are in line with previous reports showing 
that YC-1 amplifies the vasorelaxation mediated by CORM-3 (32). The effect of YC-1 and 
CORM-A1 was also examined on mean arterial pressure (MAP) in vivo. The compounds were 
injected intravenously as a bolus at a final dose of 30 µmol/kg for CORM-A1 (or iCORM-A1) 
and 1.2 µmol/kg for YC-1. When the two compounds were used in combination, YC-1 was 
administered 10 min before CORM-A1. As shown in Figure 8B (see line with solid circles), 
CORM-A1 produced a gradual and sustained decrease in MAP over time; specifically, 60 min 
after CORM-A1 injection, MAP decreased by 6.3 ± 1.5 mmHg from the initial baseline value. 
Administration of YC-1 alone (see line with solid square) or in combination with the negative 
control iCORM-A1 (see line with solid diamonds) produced only a transient decrease in MAP, 
reaching a maximum of 5.5 ± 1.0 mmHg after 10 min and returning to basal levels 50 min after 
injection. Interestingly, the combination of CORM-A1 and YC-1 (see line with solid triangles) 
produced a synergistic effect, resulting in a rapid and profound hypotension. In fact, MAP 
significantly decreased by 16.1 ± 5.6 mmHg after 10 min (P<0.05 vs. baseline or CORM-A1 
alone) and remained at this level thereafter. 
DISCUSSION 
Certain transition metal carbonyls exert interesting biological activities in so far as they 
reproduce many of the pharmacological effects mediated by CO gas and thus can be used as CO-
RMs for experimental purposes (28). Our early investigations revealed that manganese and 
ruthenium-containing carbonyl complexes (CORM-1 and CORM-2), which are soluble only in 
organic solvents (e.g., DMSO), can be safely used at low concentrations to promote relaxation of 
blood vessels and mitigate acute hypertension in vivo (28, 29). Other laboratories have 
subsequently confirmed the bioactive properties of CORM-1 and CORM-2 in mediating cerebral 
vasodilatation (35–37), smooth muscle relaxation of internal anal sphincter (38), suppression of 
smooth muscle cell proliferation (39), angiogenesis (40), inhibition of apoptosis (41, 42) and 
cardiac hyperthrophy (43), improved renal function (44), and anti-inflammatory and 
immunological responses (45, 46). More recently, the first prototype of a water-soluble carbonyl 
complex that contains the amino acid glycine covalently bound to a ruthenium metal (CORM-3) 
has been described. This compound has been reported to promote cardioprotection in both in 
vitro and in vivo models of myocardial infarction and in cardiac transplantation (30, 31), and its 
use has provided important information on how some of the pharmacological and vasoactive 
properties of CO-RMs could be exploited therapeutically (24, 25, 32). 
In this study, we report on sodium boranocarbonate, Na2[H3BCO2], as a newly identified CO-
RM that spontaneously liberates CO with a different rate compared with CORM-3. The idea of 
testing boranocarbonate originated from an interesting publication reporting the need of a CO 
source to synthesize a transition metal carbonyl ([99mTc(OH2)3(CO)3]
+) specifically designed for 
radioimaging technology (47). The preparation of this carbonyl requires the use of CO gas, 
which is impractical for use in commercial radiopharmaceutical kits (48). The solution to this 
problem has been presented in a recent study reporting the preparation of [99mTc(OH2)3(CO)3]
+ in 
physiological media using a boron-based carbonylating agent, potassium boranocarbonate, which 
acts as a CO source and a reducing agent at the same time (33). In the present study, we confirm 
the ability of sodium boranocarbonate, here termed CORM-A1, to liberate CO in aqueous 
solution and elicit pharmacological effects that are typical of CO gas. CORM-A1 does not 
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contain a transition metal but a boron atom to which a carboxyl group (COO−) is covalently 
bound. At room temperature, it is known that aqueous solutions of CORM-A1 are alkaline and 
very stable, but in the presence of hydrogen ions, the compound starts to decompose and liberate 
CO (33). CORM-A1 is involved in two acid/base equilibria as shown in Equation 1. 
The constant pKa1 is ~10, which means that CORM-A1 is fully monoprotonated at physiological 
pH. The direct precursor for CO release is the highly unstable borane-carbonyl H3B-CO formed 
after a second protonation and water cleavage, which represents the rate-limiting step. The more 
acidic the solution, the higher is the “active” concentration of double protonated CORM-A1 and 
the faster the CO release. 
By using an established myoglobin assay as well as an amperometric CO sensor, we found that 
the kinetic of CO formation from CORM-A1 is strictly pH- and temperature-dependent. 
Specifically, the rate of CO release from CORM-A1 at 37°C is much slower at pH 7.4 (Kd=0.55 
× 10−3 s–1) than pH 5.5 (Kd=5.8 × 10−3 s–1) and, most notably, slower than the rate of CO release 
previously reported for the ruthenium-based carbonyl CORM-3. Indeed, it is known from our 
recent studies that the liberation of CO from CORM-3 ([Ru(CO)3Cl(glycinate)]) in biological 
systems occurs very rapidly (within 1–5 min) (24, 30); as a consequence, CORM-3 elicits a 
correspondingly rapid relaxation in isolated vessels (24, 32). In the case of CORM-A1, its half-
life at physiological pH and temperature is ~21 min. In line with this slower release, CORM-A1 
added to isolated aortic rings precontracted with phenylephrine promoted a gradual and sustained 
vasorelaxation that was maximal after 33 min, whereas CORM-3 caused a profound relaxation 
within 4–5 min only after addition to the organ bath (see Fig. 5A). Similarly, the rate of change 
in MAP observed in vivo after injection of rats with CORM-3 or CORM-A1 is in agreement with 
the different CO-release characteristics of these two compounds. Indeed, the gradual decrease in 
MAP over time after infusion of CORM-A1 (6.3 mmHg drop within 60 min) is in contrast with 
the prompt hypotensive effect (9.4 mmHg drop within 10 min) reported recently for CORM-3 
(see ref 32). These results suggest a strong correlation between the distinct rate of CO release 
from CORM-A1 and CORM-3 and their specific pharmacological activities, which appear to be 
dictated by the rate of CO liberation. This idea is further corroborated by the measurements of 
HbCO levels following exposure of human blood to CORM-A1, where the gradual and time-
dependent formation of HbCO indicates a slow and controlled release of CO from CORM-A1 
even in a complex biological fluid such as blood. It is worth highlighting that while micromolar 
concentrations of CORM-A1 are sufficient to elicit pharmacological effects both in isolated 
vessels and in vivo, millimolar concentrations are needed to cause significant increases in HbCO 
levels in human blood. The measurements on HbCO were performed in isolated blood, thereby 
eliminating all the other potential cellular targets that could be affected by CO in an in vivo 
situation. These considerations suggest that CO liberated from CORM-A1 influences intra- 
and/or extracellular targets and modulates physiological functions at far lower concentrations 
than those required to change HbCO levels. 
There is little doubt that the biochemical and pharmacological effects elicited by CORM-A1 are 
mediated by CO. First, linear correlations can be obtained between the levels of MbCO formed 
(R2=0.99) or the amounts of CO detected with the electrode (R2=0.98) and the concentrations of 
CORM-A1 used. Second, the extent of vasorelaxation elicited by CORM-A1 over time was 
concentration-dependent. Third, when the compound was depleted of CO (iCORM-A1) by 
adding acid to the solution, no CO was detected with either the Mb assay or the CO sensor and 
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no vasorelaxation could be observed. In addition, NaBH4, which was used as another negative 
control to verify any possible contribution of boron in the bioactivity mediated by CORM-A1, 
was equally ineffective. The extent of vasodilatation exerted by CORM-A1 was also 
significantly attenuated by addition of myoglobin to the organ bath, confirming the direct 
involvement of CO in the observed biological effects. The experiments conducted to assess 
changes in MAP and vessel contractility by the combined administration of CORM-A1 and YC-
1, a well-known benzylindazole derivative that activates the guanylate cyclase/cGMP pathway, 
further supported the role of CO as a potential pharmaceutical agent. While YC-1 alone or 
iCORM-A1 plus YC-1 slightly and only temporarily decreased MAP, the combination of 
CORM-A1 and YC-1 produced a significant and sustained hypotensive effect in vivo. Similarly, 
the presence of YC-1 markedly amplified the extent of vasodilatation caused by CORM-A1 in 
isolated aortas. 
The effect of YC-1 indicates that guanylate cyclase is a target for CO in the vasorelaxation 
mediated by CORM-A1. This is also supported by the data showing that an inhibitor of 
guanylate cyclase (ODQ) significantly decreased the extent of dilatation caused by CORM-A1, 
thus confirming the results previously obtained with the metal carbonyl complex CORM-3 (32). 
However, blockade of potassium channels with glibenclamide, which is also known to partially 
attenuate the vasorelaxation by CORM-3 (32), did not have any effect on the vasoactivity 
elicited by CORM-A1. Notably, inhibition of NO synthase activity by L-NAME or removal of 
the endothelium, which significantly inhibited CORM-3-mediated vessel relaxation (32), failed 
to prevent the pharmacological effects of CORM-A1, suggesting that the action of CO exerted 
through the reactivity of boranocarbonate is independent of the endothelial function. At present, 
we do not have a precise answer for this discrepancy, and future experiments will examine these 
aspects more in detail. However, we know that the intrinsic chemical nature of the two 
compounds is very different since CORM-A1, unlike CORM-3, possesses some reducing 
capacities in addition to its ability to liberate CO (33) and thus may differently affect the 
response of the vessels. Collectively, these data reveal that CORM-A1 promotes an endothelium-
independent relaxation response that is partially mediated by activation of guanylate cyclase and 
emphasize the distinct nature of this compound, which liberates CO into aqueous solutions with 
a kinetic that leads to a gradual relaxing and hypotensive effect. 
Thus, the data of our present and previous studies (24, 29, 32) confirm that both transition metal 
carbonyls and sodium boranocarbonate meet the criteria of pharmacologically active CO-RMs. 
Our attempt to diversify the portfolio of CO-RMs that possess a variety of chemical 
characteristics (i.e., water-soluble vs. lipid-soluble, slow vs. fast releasers) will help to elucidate 
the biological function of cellular targets that are responsive to CO and will facilitate the 
therapeutic delivery of CO in a safe, measurable, and controllable fashion (49). For instance, 
irrespective of their solubility in DMSO or aqueous solutions, the metal carbonyls tested so far 
have been demonstrated to promptly liberate CO upon addition to biological systems, as ligands 
present in the extracellular or plasma environment (i.e., phosphate, glutathione) appear to 
accelerate dissociation of CO from the metal center (24). In the case of the water-soluble 
CORM-3, the release of CO is further accelerated when this compound is added to a solution 
containing myoglobin (30). Therefore, CORM-3 would fall into a category of compounds that 
release CO very rapidly (“fast releasers”) in biological systems, which would be ideal for those 
therapeutic applications where CO acts as a prompt signaling mediator. However, chemicals that 
release CO with a slow kinetic (“slow releasers”), as in the case of CORM-A1, could be more 
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versatile in the treatment of certain chronic diseases. To this extent, CORM-A1 might mimic 
more closely the natural function of heme oxygenase, which is expected to generate endogenous 
CO in a sustained manner particularly in vascular and inflammatory disease states typified by up-
regulation of the inducible HO-1 (5, 10). 
ACKNOWLEDGMENTS 
We thank Dr. James Clark for his contribution in conducting the experiments on mean arterial 
pressure and HbCO measurements. Dr. Roberta Foresti is supported by a fellowship from the 
Dunhill Medical Trust. 
REFERENCES 
1. Ryter, S. W., Morse, D., and Choi, A. M. (2004) Carbon Monoxide: To Boldly Go Where 
NO Has Gone Before. Sci. STKE. 2004, RE6 
2. Maines, M. D. (1997) The heme oxygenase system: a regulator of second messenger gases. 
Annu. Rev. Pharmacol. Toxicol. 37, 517–554 
3. Motterlini, R., Gonzales, A., Foresti, R., Clark, J. E., Green, C. J., and Winslow, R. M. 
(1998) Heme oxygenase-1-derived carbon monoxide contributes to the suppression of acute 
hypertensive responses in vivo. Circ. Res. 83, 568–577 
4. Sammut, I. A., Foresti, R., Clark, J. E., Exon, D. J., Vesely, M. J. J., Sarathchandra, P., 
Green, C. J., and Motterlini, R. (1998) Carbon monoxide is a major contributor to the 
regulation of vascular tone in aortas expressing high levels of haeme oxygenase-1. Br. J. 
Pharmacol. 125, 1437–1444 
5. Otterbein, L. E., Soares, M. P., Yamashita, K., and Bach, F. H. (2003) Heme oxygenase-1: 
unleashing the protective properties of heme. Trends Immunol. 24, 449–455 
6. Foresti, R., Green, C. J., and Motterlini, R. (2004) Generation of bile pigments by heme 
oxygenase: a refined cellular stratagem in response to stressful insults. Biochem. Soc. Symp. 
71, 177–192 
7. Naughton, P., Foresti, R., Bains, S., Hoque, M., Green, C. J., and Motterlini, R. (2002) 
Induction of heme oxygenase-1 by nitrosative stress: a role for nitroxyl anion. J. Biol. Chem. 
277, 40666–40674 
8. Motterlini, R., Green, C. J., and Foresti, R. (2002) Regulation of heme oxygenase-1 by 
redox signals involving nitric oxide. Antiox.Redox Signal. 4, 615–624 
9. Motterlini, R., Foresti, R., Bassi, R., Calabrese, V., Clark, J. E., and Green, C. J. (2000) 
Endothelial heme oxygenase-1 induction by hypoxia: modulation by inducible nitric oxide 
synthase (iNOS) and S-nitrosothiols. J. Biol. Chem. 275, 13613–13620 
10. Foresti, R., and Motterlini, R. (1999) The heme oxygenase pathway and its interaction with 
nitric oxide in the control of cellular homeostasis. Free Rad.Res. 31, 459–475 
Page 11 of 24
(page number not for citation purposes)
11. Wang, R. (1998) Resurgence of carbon monoxide: an endogenous gaseous vasorelaxing 
factor. Can. J. Physiol. Pharmacol. 76, 1–15 
12. Wang, R., Wang, Z. Z., and Wu, L. Y. (1997) Carbon monoxide-induced vasorelaxation and 
the underlying mechanisms. Br. J. Pharmacol. 121, 927–934 
13. Wakabayaski, Y., Takamiya, R., Mizuki, A., Kyokane, T., Goda, N., Yamaguchi, T., 
Takeoka, S., Tsuchida, E., Suematsu, M., and Ishimura, Y. (1999) Carbon monoxide 
overproduced by heme oxygenase-1 causes a reduction of vascular resistance in perfused rat 
liver. Am. J. Physiol. 277, G1088–G1096 
14. Morita, T., Mitsialis, S. A., Koike, H., Liu, Y. X., and Kourembanas, S. (1997) Carbon 
monoxide controls the proliferation of hypoxic vascular smooth muscle cells. J. Biol. Chem. 
272, 32804–32809 
15. Peyton, K. J., Reyna, S. V., Chapman, G. B., Ensenat, D., Liu, X. M., Wang, H., Schafer, A. 
I., and Durante, W. (2002) Heme oxygenase-1-derived carbon monoxide is an autocrine 
inhibitor of vascular smooth muscle cell growth. Blood 99, 4443–4448 
16. Sato, K., Balla, J., Otterbein, L., Smith, R. N., Brouard, S., Lin, Y., Csizmadia, E., Sevigny, 
J., Robson, S. C., Vercellotti, G., et al. (2001) Carbon monoxide generated by heme 
oxygenase-1 suppresses the rejection of mouse-to-rat cardiac transplants. J. Immunol. 166, 
4185–4194 
17. Sacerdoti, D., Abraham, N. G., Oyekan, A. O., Yang, L., Gatta, A., and McGiff, J. C. (2004) 
Role of the heme oxygenases in abnormalities of the mesenteric circulation in cirrhotic rats. 
J. Pharmacol. Exp. Ther. 308, 636–643 
18. Otterbein, L. E., Bach, F. H., Alam, J., Soares, M., Tao Lu, H., Wysk, M., Davis, R. J., 
Flavell, R. A., and Choi, A. M. (2000) Carbon monoxide has anti-inflammatory effects 
involving the mitogen-activated protein kinase pathway. Nat. Med. 6, 422–428 
19. Chapman, J. T., Otterbein, L. E., Elias, J. A., and Choi, A. M. (2001) Carbon monoxide 
attenuates aeroallergen-induced inflammation in mice. Am. J. Physiol. Lung Cell. Mol. 
Physiol. 281, L209–L216 
20. Brouard, S., Otterbein, L. E., Anrather, J., Tobiasch, E., Bach, F. H., Choi, A. M., and 
Soares, M. P. (2000) Carbon monoxide generated by heme oxygenase 1 suppresses 
endothelial cell apoptosis. J. Exp. Med. 192, 1015–1026 
21. Otterbein, L. E., Zuckerbraun, B. S., Haga, M., Liu, F., Song, R., Usheva, A., Stachulak, C., 
Bodyak, N., Smith, R. N., Csizmadia, E., et al. (2003) Carbon monoxide suppresses 
arteriosclerotic lesions associated with chronic graft rejection and with balloon injury. Nat. 
Med. 9, 183–190 
22. Bak, I., Szendrei, L., Turoczi, T., Papp, G., Joo, F., Das, D. K., de Leiris, J., Der, P., Juhasz, 
B., Varga, E., et al. (2003) Heme oxygenase-1-related carbon monoxide production and 
Page 12 of 24
(page number not for citation purposes)
ventricular fibrillation in isolated ischemic/reperfused mouse myocardium. FASEB J. 17, 
2133–2135 
23. Fujita, T., Toda, K., Karimova, A., Yan, S. F., Naka, Y., Yet, S. F., and Pinsky, D. J. (2001) 
Paradoxical rescue from ischemic lung injury by inhaled carbon monoxide driven by 
derepression of fibrinolysis. Nat. Med. 7, 598–604 
24. Motterlini, R., Mann, B. E., Johnson, T. R., Clark, J. E., Foresti, R., and Green, C. J. (2003) 
Bioactivity and pharmacological actions of carbon monoxide-releasing molecules. Curr. 
Pharm. Des. 9, 2525–2539 
25. Johnson, T. R., Mann, B. E., Clark, J. E., Foresti, R., Green, C. J., and Motterlini, R. (2003) 
Metal carbonyls: a new class of pharmaceuticals? Angew. Chem. Int. Ed. Engl. 42, 3722–
3729 
26. Motterlini, R. (2002) Vasoactive properties of carbon monoxide-releasing molecules.  
Biomed. Pharmacother. 56, 349–350 
27. Piantadosi, C. A. (2002) Biological chemistry of carbon monoxide. Antioxid. Redox Signal. 
4, 259–270 
28. Motterlini, R., Foresti, R., and Green, C. J. (2002) Studies on the development of carbon 
monoxide-releasing molecules: potential applications for the treatment of cardiovascular 
dysfunction. In Carbon Monoxide and Cardiovascular Functions (Wang, R., ed) pp. 249-
271, CRC Press, Boca Raton, Florida.  
29. Motterlini, R., Clark, J. E., Foresti, R., Sarathchandra, P., Mann, B. E., and Green, C. J. 
(2002) Carbon monoxide-releasing molecules: characterization of biochemical and vascular 
activities. Circ. Res. 90, E17–E24 
30. Clark, J. E., Naughton, P., Shurey, S., Green, C. J., Johnson, T. R., Mann, B. E., Foresti, R., 
and Motterlini, R. (2003) Cardioprotective actions by a water-soluble carbon monoxide-
releasing molecule. Circ. Res. 93, e2–e8 
31. Guo, Y., Stein, A. B., Wu, W. J., Tan, W., Zhu, X., Li, Q. H., Dawn, B., Motterlini, R., and 
Bolli, R. (2004) Administration of a CO-Releasing Molecule at the Time of Reperfusion 
Reduces Infarct Size In Vivo. Am. J. Physiol. Heart Circ. Physiol. 286, H1649–H1653 
32. Foresti, R., Hammad, J., Clark, J. E., Johnson, R. A., Mann, B. E., Friebe, A., Green, C. J., 
and Motterlini, R. (2004) Vasoactive properties of CORM-3, a novel water-soluble carbon 
monoxide-releasing molecule. Br. J. Pharmacol. 142, 453–460 
33. Alberto, R., Ortner, K., Wheatley, N., Schibli, R., and Schubiger, A. P. (2001) Synthesis and 
properties of boranocarbonate: a convenient in situ CO source for the aqueous preparation of 
[(99m)Tc(OH(2))3(CO)3]+. J. Am. Chem. Soc. 123, 3135–3136 
34. Friebe, A., Schultz, G., and Koesling, D. (1996) Sensitizing soluble guanylyl cyclase to 
become a highly CO-sensitive enzyme. EMBO J. 15, 6863–6868 
Page 13 of 24
(page number not for citation purposes)
35. Fiumana, E., Parfenova, H., Jagger, J. H., and Leffler, C. W. (2003) Carbon monoxide 
mediates vasodilator effects of glutamate in isolated pressurized cerebral arterioles of 
newborn pigs. Am. J. Physiol. Heart Circ. Physiol. 284, H1073–H1079 
36. Koneru, P., and Leffler, C. W. (2004) Role of cGMP in carbon monoxide-induced cerebral 
vasodilation in piglets. Am. J. Physiol. Heart Circ. Physiol. 286, H304–H309 
37. Xi, Q., Tcheranova, D., Parfenova, H., Horowitz, B., Leffler, C. W., and Jaggar, J. H. (2004) 
Carbon monoxide activates KCa channels in newborn arteriole smooth muscle cells by 
increasing apparent Ca2+ sensitivity of a-subunits. Am. J. Physiol. Heart Circ. Physiol. 286, 
H610–H618 
38. Rattan, S., Haj, R. A., and De Godoy, M. A. (2004) Mechanism of internal anal sphincter 
relaxation by CORM-1, authentic CO, and NANC nerve stimulation. Am. J. Physiol. 
Gastrointest. Liver Physiol. 287, G605–G611 
39. Stanford, S. J., Walters, M. J., Hislop, A. A., Haworth, S. G., Evans, T. W., Mann, B. E., 
Motterlini, R., and Mitchell, J. A. (2003) Heme oxygenase is expressed in human pulmonary 
artery smooth muscle where carbon monoxide has an anti-proliferative role. Eur. J. 
Pharmacol. 473, 135–141 
40. Jozkowicz, A., Huk, I., Nigisch, A., Weigel, G., Dietrich, W., Motterlini, R., and Dulak, J. 
(2003) Heme oxygenase-1 and angiogenic activity of endothelial cells: stimulation by 
carbon monoxide, inhibition by tin protoporphyrin IX. Antioxid. Redox Signal. 5, 155–162 
41. Choi, B. M., Pae, H. O., and Chung, H. T. (2003) Nitric oxide priming protects nitric oxide-
mediated apoptosis via HEME OXYGENASE-1 induction. Free Radic. Biol. Med. 34, 
1136–1145 
42. Choi, B. M., Pae, H. O., Kim, Y. M., and Chung, H. T. (2003) Nitric oxide-mediated 
cytoprotection of hepatocytes from glucose deprivation-induced cytotoxicity: involvement 
of heme oxygenase-1. Hepatology 37, 810–823 
43. Tongers, J., Fiedler, B., Konig, D., Kempf, T., Klein, G., Heineke, J., Kraft, T., Gambaryan, 
S., Lohmann, S. M., Drexler, H., et al. (2004) Heme oxygenase-1 inhibition of MAP 
kinases, calcineurin/NFAT signaling, and hypertrophy in cardiac myocytes. Cardiovasc. 
Res. 63, 545–552 
44. Arregui, B., Lopez, B., Salom, M. G., Valero, F., Navarro, C., and Fenoy, F. J. (2004) Acute 
renal hemodynamic effects of dimanganese decacarbonyl and cobalt protoporphyrin. Kidney 
Int. 65, 564–574 
45. Lee, T. S., Tsai, H. L., and Chau, L. Y. (2003) Induction of heme oxygenase-1 expression in 
murine macrophage is essential for the anti-inflammatory effect of 15-deoxy-delta-12,15-
prostaglandin J2. J. Biol. Chem. 278, 19325–19330 
46. Vannacci, A., Di Felice, A., Giannini, L., Marzocca, C., Pierpaolo, S., Zagli, G., Masini, E., 
and Mannaioni, P. F. (2004) The effect of a carbon monoxide-releasing molecule on the 
Page 14 of 24
(page number not for citation purposes)
immunological activation of guinea-pig mast cells and human basophils. Inflamm. Res. 53, 
Suppl 1, S9–S10 
47. Waibel, R., Alberto, R., Willuda, J., Finnern, R., Schibli, R., Stichelberger, A., Egli, A., 
Abram, U., Mach, J. P., Pluckthun, A., et al. (1999) Stable one-step technetium-99m 
labeling of His-tagged recombinant proteins with a novel Tc(I)-carbonyl complex. Nat. 
Biotechnol. 17, 897–901 
48. Alberto, R., Schibli, R., Egli, A., Schubiger, A. P., Abram, U., and Kaden, T. A. (1998) A 
novel organometallic aqua complex of technetium for the labeling of biomolecules: 
Synthesis of [Tc-99m(OH2)(3)(CO)(3)](+) from [(TcO4)-Tc-99m](-) in aqueous solution 
and its reaction with a bifunctional ligand. J. Am. Chem. Soc. 120, 7987–7988 
49. Chatterjee, P. K. (2004) Water-soluble carbon monoxide-releasing molecules: helping to 
elucidate the vascular activity of the 'silent killer'. Br. J. Pharmacol. 142, 391–393 
Received June 29, 2004; accepted October 13, 2004. 
 
 
Page 15 of 24
(page number not for citation purposes)
Equation 1 
 
 
 
 
 
 
 
 
 
 
 
-H+ 
Ka1 
+H+ 
-H+ 
Ka1 
+H+
-H+ 
Ka2 
[H3BCOO]
2− [H3BCOOH]
− [H3BCOOH2]
 
{H3BCO}
 
−H2O 
CO 
Page 16 of 24
(page number not for citation purposes)
Fig. 1 
 
 
Figure 1. The rate of conversion of deoxy-myoglobin (Mb) to carbon monoxide myoglobin (MbCO) by CORM-A1 
is pH-dependent. The conversion of Mb to MbCO was followed over time by measuring the changes in the absorption 
spectra of this protein at pH 7.4 (A), 7.0 (B), 6.5 (C), and 5.5 (D) after addition of 60 µM CORM-A1. The solutions of Mb 
were prepared in phosphate buffer and the spectra run at 37°C as reported in Materials and Methods. The maximal 
absorption peak of Mb at 560 nm (see Figure 1A, curve with filled square) is gradually converted over time by CORM-A1 
to spectra typical of MbCO, with two maximal absorption peaks at 540 and 578, respectively (see curve with filled 
diamond). 
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Fig. 2 
 
 
Figure 2. Quantification of CO liberated from CORM-A1 using the myoglobin assay. A) The amount of MbCO 
formed over time at 37°C was measured after addition of CORM-A1 (60 µM) to the Mb solution, and the half-lives (t1/2) of 
this compound at different pHs were calculated from the fitted curves. Note that the inactive compound (iCORM-A1) did 
not generate any MbCO. B, C) Spectra of MbCO formation after addition of different concentrations of CORM-A1 to Mb 
at pH 5.5 and relative standard curve. The data indicate that the reaction favoring the release of CO from CORM-A1 goes 
to completion as approximately one mole of CO per mole of CORM-A1 is formed. The data are represented as mean ± SE 
of five independent experiments. 
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Fig. 3 
 
 
Figure 3. Quantification of CO liberated from CORM-A1 using an amperometric CO sensor. A) Typical tracings 
showing the current measured over time by the CO electrode upon addition of 100 µM CORM-A1 at 37°C. Note that the 
liberation of CO from CORM-A1 is much faster at pH 5.5 than at pH 7.4 and that no CO is detected after addition of the 
inactive compound (iCORM-A1) B) Calibration of the CO electrode by plotting the maximal currents measured with 
increasing concentrations of CORM-A1 at pH 5.5 and 37°C. The data are represented as mean ± SE of five independent 
experiments. C, D) Typical tracings of the CO electrode showing that the rate of CO release over time from CORM-A1 (20 
µM) is strictly dependent on pH (C) and temperature (D). See Materials and Methods as well as Results for more technical 
details. 
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Fig. 4 
 
                                    
Figure 4. Formation of carboxyhemoglobin (HbCO) in isolated human blood incubated with CORM-A1. A) Freshly 
collected human blood was incubated with different concentrations of CORM-A1 at 37°C and HbCO levels detected after 
15 or 45 min using a blood gas analyzer. B) Time course of HbCO formation after incubation of human blood (37°C) with 
18 mM CORM-A1. In both graphs, data are expressed as mean ± SE of four independent experiments. 
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Fig. 5 
 
                       
 
Figure 5. Vasodilatation elicited by CORM-A1: a comparison with CORM-3. A) Representative recording of 
isometric tension in aortic rings precontracted with phenylephrine (Phe, 1 µM) and subsequently subjected to a bolus 
addition of CORM-3 or CORM-A1 (100 µM). Typically, CO-RMs were added to the water bath containing aortic rings 
once phenylephrine had produced a stable contraction; CORM-3 caused profound relaxation within a few minutes of 
addition, whereas CORM-A1 required ~33 min to elicit maximal vasorelaxation. B) Concentration-dependent relaxation 
responses to CORM-A1 in aortic rings precontracted with phenylephrine. The vasodilatation is expressed as percentage of 
the maximal precontraction. Data represent the mean ± SE of six independent experiments. *P < 0.05 compared with 
control (CON). 
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Fig. 6 
 
                                                                           
Figure 6. The vasorelaxation by CORM-A1 is mediated by CO. A) Representative recording of isometric tension in 
aortic rings precontracted with phenylephrine (Phe, 1 µM) and subsequently subjected to a bolus addition of 80 µM 
CORM-A1, iCORM-A1, or sodium borohydride (Na2BH4). iCORM-A1, which does not release CO, and Na2BH4 were 
used as negative controls (see Materials and Methods as well as Results for details). B) Vasodilatory responses to 80 µM 
CORM-A1, iCORM-A1, and Na2BH4 in aortic rings precontracted with phenylephrine. The vasodilatation is expressed as 
percentage of the maximal precontraction. Data represent mean ± SE of six independent experiments. *P < 0.05 compared 
with iCORM-A1 and Na2BH4. C) The relaxation mediated by CORM-A1 (80 µM) in aortic isolated rings is attenuated by 
Mb (100 µM). The relaxation is expressed as a percentage of the maximal precontraction, and the values represent 
relaxation measured 10 min after addition of CORM-A1. Data represent mean ± SE of six independent experiments.  
*P < 0.05 compared with CORM-A1. 
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Figure 7. Mechanisms of vasorelaxation mediated by CORM-A1. A) Vasodilatory responses to CORM-A1 in the 
presence of a potassium channel blocker (glibenclamide, GLI) or a guanylate cyclase inhibitor (ODQ). Aortic rings were 
pretreated with GLI (10 µM) or ODQ (30 µM) before contraction with phenylephrine, and then CORM-A1 was added. *P 
< 0.05 compared with CORM-A1. B) Vasodilatory responses to CORM-A1 in the presence of a NO synthase inhibitor 
(NG-nitro-L-arginine-methyl ester, L-NAME). Aortic rings were incubated with L-NAME (100 µM) for 30 min before 
contraction with phenylephrine, and then CORM-A1 (80 µM) was added. C) Effect of CORM-A1 on endothelium-denuded 
vessels. The endothelium of aortic rings was gently removed (-End) as described in Materials and Methods, and the 
vasodilatory response to CORM-A1 (80 µM) was compared with that of intact rings (+End). In all graphs, the relaxation is 
expressed as percentage of the maximal precontraction. Data represent mean ± SE of six independent experiments. 
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Figure 8. YC-1 potentiates CORM-A1-mediated vasodilatation in vitro and in vivo. A) Effect of YC-1 on CORM-
A1-mediated vasorelaxation in isolated vessels. Aortic rings were pretreated with 1 µM YC-1 (30 min before contraction 
with phenylephrine) and then subjected to a bolus addition of CORM-A1 (1, 10, and 20 µM, respectively). The relaxation 
is expressed as a percentage of the maximal precontraction. Data represent mean ± SE of six independent experiments. *P < 
0.05 compared with YC-1 alone. B) Effect of YC-1 on mean arterial pressure (MAP) in vivo. Rats were anesthetized and 
chronically catheterized as described in Materials and Methods. CORM-A1 (30 µmol/kg, i.v.) or the inactive compound 
(iCORM-A1) was injected alone or in combination with YC-1 (1.2 µmol/kg, i.v.) and mean arterial pressure (MAP) was 
measured over time. Data represent mean ± SE of four to five independent experiments. *P < 0.05 compared with baseline 
values (time, –10 min); †P < 0.05 compared with YC-1, CORM-A1, or iCORM-A1 plus YC-1. 
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